Showing 731-740 of 9099 results for "".
Prevalence of Prurigo Nodularis Across Adult Populations
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/prevalence-of-prurigo-nodularis-across-adult-populations/48774/James Q. Del Rosso, DO, FAOCD, discusses the clinical presentation of prurigo nodularis and how it differs from atopic dermatitis.Roflumilast Cream, 0.15%, for Atopic Dermatitis
https://practicaldermatology.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formulTime Is Hair: An Update on the Diagnosis and Treatment of Scarring Alopecias in Patients with Darker Skin Tones
https://practicaldermatology.com/programs/practical-dermatology/time-is-hair-an-update-on-the-diagnosis-and-treatment-of-scarring-alopecia-in-patients-with-darker-skin-tones/18198/In part two of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Dr. Andrew Alexis, a dermatologist from New York City and the President of the Skin of Color Society; Dr. Corey Hartman, a dermatologist in Birmingham, Alabama; and Dr. Janiene Luke, a dermatoloAdvancing Digital Medicine in Dermatology
https://practicaldermatology.com/programs/practical-dermatology/advancing-digital-medicine-in-dermatology/18187/The Digital Medicine Society (DiME) is a global nonprofit dedicated to advancing the ethical, effective, equitable, and safe use of digital medicine to redefine health care and improve lives. DiME recently released a new set of resources, available at www.dimesociety.org/access-resources/, to advancNew FDA Approval for AD
https://practicaldermatology.com/series/c-suite-chats/new-fda-approval-for-ad/29911/Phil Brown, MD, JD, Dermatologic Scientific Lead at Organon, talks about the importance of a new FDA-approved topical solution for treating atopic dermatitis.DermWireTV: Atopic Dermatitis Pipeline Watch, a Potential New Skin Cancer Treatment; Demystifying Itch, and the Premiere of PA Perspectives
https://practicaldermatology.com/topics/practice-management/dermwiretv-atopic-dermatitis-pipeline-watch-a-potential-new-skin-cancer-treatment-demystifying-itch-and-the-premiere-of-pa-perspectives/20228/Escient Pharmaceuticals, Rapt Therapeutics, and Connect Biopharma each report positive results from early clinical studies in AD. Finnish researchers discover a potential treatment for cutaneous squamous cell carcinoma in an existing chemotherapy drug. Research out of Harvard Medical School links ecLet's Talk About Rosacea and Acne
https://practicaldermatology.com/conferences/scale-2023/acne-and-rosacea/20188/Hilary Baldwin, MD, shares pearls for treating papopustular rosacea, vascular rosacea, and acne.Weighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clUnmet Needs in Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37140/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, talks about what he feels are the greatest unmet needs in atopic dermatitis.Biologics in the Treatment Landscape for Atopic Dermatitis Patients
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37144/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, describes how newly available biologics in recent years have impact clinicians’ ability to treat atopic